On March 4, 2024, the CAPability-01 study led by Professor Xu Ruihua and Professor Wang Feng from the Sun Yat-sen University Cancer Center was published in the prestigious academic journal Nature Medicine (IF = 82.9) [1]. As one of the most valuable sub-journals of Nature, the publication in Nature Medicine reflects the recognition of academic authority for the CAPability-01 study. 

This study showed that for patients with microsatellite stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC), the three-drug regimen of chidamide + sintilimab + bevacizumab for the third-line and beyond treatment resulted in an 18-week PFS rate of 64.0%, an ORR of 44.0%, and a median PFS of 7.3 months. Thus, this combined therapy is a promising treatment option for patients with MSS/pMMR advanced CRC. 
 
Chidamide is the world's first subtype-selective HDAC oral inhibitor independently developed by Chipscreen Biosciences. It has been approved for the indications of peripheral T-cell lymphoma (PTCL) and HR+/Her2- advanced breast cancer in China and has shown great potential in clinical studies of various solid tumors. At this important historic moment, the CAPability-01 study once again reveals the highly competitive application prospect of the three-drug regimen led by chidamide in the treatment of mCRC.